Question-and-Answer Session
Operator
(Operator instructions) We'll take our first question from Brett Holley with Oppenheimer & Co.
Michael Barrick – Oppenheimer & Co.
Oh, hi. This is actually Michael Barrick [ph] on behalf of Brett. I just have a question about the colorectal cancer trial. Acknowledging that you just completed enrollment in the study, can you provide any information about the number of patients and the duration of follow-up that you'll presenting at ASCO?
Jerry McMahon
As we indicated, we completed enrollment and we plan to provide a more complete updated Phase I data information at ASCO, as well as some early data related to the Phase II trial for those patients that have been treated long enough with drug. And that's really the only guidance we are giving at this point.
Michael Barrick – Oppenheimer & Co.
Okay. Okay, great. For SPEAR, as enrollment continues and you are continuing to collect more information about events, is the event rate more or less tracking along what you are expecting at the beginning of the study?
Jerry McMahon
We are not providing any information in regard to event rate. Again, we made a lot of progress and continue to make a lot of progress with this trial, and we are focused on analyzing the data from this trial in the middle of next year.
Michael Barrick – Oppenheimer & Co.
Okay, great. Thank you.
Operator
We'll take our next question from Matt Osborne with Lazard.
Matt Osborne – Lazard Capital Markets
Hi, guys. Thanks for taking the question. Jerry, can you comment at least on the FOLPI versus FOLFOX? Will it be data from the independent reviewers or from the investigator reviewed CAT scans?
Jerry McMahon
This is a preliminary – this is an open-label study, so we have the ability to look at the data and it provides us with an opportunity to get a first, if you will, glimpse of what's going on in our Phase II trial. We do have an independent review of the neurology. We have a neurologist who is involved with the study, who provides an analysis of that safety aspect of the trial in a blinded fashion. But the remainder of the data is data that we analyze ourselves at the company to provide an appropriate scientific disclosure for ASCO.
Matt Osborne – Lazard Capital Markets
Great. Can you remind us in this study, were patients allowed stop-and-go treatments with oxaliplatin in the FOLFOX regimen?
- To read the full transcript on Seeking Alpha, click here »
